# Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

> **NCT00076336** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 232 (actual)

## Conditions studied

- Hepatitis
- Hepatitis B, Chronic
- Cirrhosis

## Interventions

- **DRUG:** Telbivudine
- **DRUG:** Lamivudine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00076336
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2011-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076336, "Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00076336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*